Quoin Pharmaceuticals' Actinium Advances Targeted Cancer Therapies with Promising Results

Actinium Pharmaceuticals Advances Targeted Therapies for Cancer Treatment

Actinium Pharmaceuticals, Inc., a prominent player in the field of targeted radiotherapies, is making significant strides in the development of innovative cancer treatments. The company is primarily focused on its lead product candidate, ATNM-400, which represents a breakthrough in radiotherapy targeting Ac-225. This treatment specifically addresses prostate cancer and non-small cell lung cancer (NSCLC), diseases notorious for their high mortality rates. By concentrating on metastatic castration-resistant prostate cancer (mCRPC), ATNM-400 targets antigens linked to disease progression, offering a promising alternative to existing therapies.

Recent preclinical data highlights the efficacy of ATNM-400, demonstrating superior results compared to the androgen receptor inhibitor enzalutamide (Xtandi®) and the Pluvicto® radiotherapy. These findings suggest that ATNM-400 not only provides durable tumor control but also proves effective against prostate cancer models that show resistance to conventional treatments. Furthermore, in NSCLC, ATNM-400 exhibits impressive performance, surpassing EGFR-targeting therapies such as osimertinib (TARGRISSO®) and showcasing synergistic effects when paired with these existing therapies. This positions Actinium as an influential contender in the oncology space, particularly for patients with limited treatment options.

In addition to ATNM-400, Actinium is also advancing its candidate, Actimab-A, which targets CD33 and is being developed for acute myeloid leukemia (AML). Actimab-A has shown remarkable promise, particularly in patients who have relapsed or are refractory to previous treatments, achieving high rates of Complete Remissions (CR) and measurable residual disease (MRD) negativity. This progress is not only indicative of the drug’s potential effectiveness but also suggests improved survival outcomes for patients facing this aggressive cancer. As Actinium moves forward with a pivotal Phase 2/3 trial for Actimab-A, the collaboration with the National Cancer Institute (NCI) under a Cooperative Research and Development Agreement (CRADA) underscores the company’s commitment to enhancing its research capabilities and ultimately improving patient care.

The participation of Actinium’s Chairman and CEO Sandesh Seth in the upcoming Stephens Biotechnology Virtual Fireside Chat highlights the company’s proactive approach to engaging with investors and stakeholders. This event will provide an opportunity for management to share insights into their innovative pipeline and the advancements being made in targeted cancer therapies, reinforcing Actinium's position as a leader in the industry.